Non langerhans cell histiocytoses in genitalia: A rare entity
DOI:
https://doi.org/10.66344/jpad.v34i3.2581Keywords:
Non-Langerhans cell, cyclophosphamide, immunohistochemistryAbstract
A 35 year old man presented with multiple reddish to skin colored scrotal swellings for the last 8 to 10 months. On biopsy, well circumscribed dense nodular infiltrate composed of histiocytes, lymphocytes and stray plasma cells. On IHC: CD 68 +ve, but CD1a, S100, Langerin, BRAFV600E, CD30 were negative. Based on HPE and IHC reports, a diagnosis of non-Langerhans cell histiocytosis was made. Initially the lesions were treated with intra-lesional corticosteroids, without any significant improvement. As a newer therapy, we tried oral cyclophosphamide 50 mg BD for 2 months, followed by 50 mg OD as maintenance dose, no new lesions were noted.
References
1. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-81.
2. Weitzman S, Jaffe R. The non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45(3):256-64.
3. Newman B, Hu W, Nigro K, Gilliam AC. Aggressive histiocytic disorders that can involve the skin. J Am Acad Dermatol. 2007;56(2):302-16.
doi: 10.1016/j.jaad.2006.06.010. Epub 2006 Oct 9. PMID: 17097374.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Shiladitya Chowdhury, Dyuti Das, Prodip Sarkar, Supratim Karmakar, Partha Sarathi Nayak, Ramesh Chandra Gharami
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
